Cooperative effects of tumor necrosis factor-alpha and 1,25-dihydroxyvitamin D3 on growth inhibition, differentiation, and c-myc reduction in human promyelocytic leukemia cell line HL-60.
The simultaneous addition of recombinant human tumor necrosis factor-alpha (rTNF-alpha) and 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) synergistically induced growth inhibition and differentiation of the human promyelocytic leukemia cell line HL-60. A significantly greater reduction in c-myc mRNA level was also observed after a 20-h combined treatment with rTNF-alpha and 1,25-(OH)2D3 than was observed following administration of either agent alone. These results suggest that rTNF-alpha and 1,25-(OH)2D3 induce HL-60 cell growth inhibition through different molecular mechanisms, and that their simultaneous administration could provide a new approach to the treatment of cancer.
Katakami
Y
Y
Department of Medicine (Third Division), Kobe University School of Medicine, Japan.
Nakao
Y
Y
Katakami
N
N
Koizumi
T
T
Ogawa
R
R
Yamada
H
H
Takai
Y
Y
Fujita
T
T
D002117:Calcitriol / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000473:pathology*; D009857:Oncogenes; D012333:RNA, Messenger / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D002117:Calcitriol